UroGen Pharma Ltd. (FRA:UR8)

Market Cap	837.14M +77.5%
Revenue (ttm)	82.26M +8.0%
Net Income	-140.32M
EPS	-2.95
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	18.20
Previous Close	18.50
Day's Range	18.20 - 18.20
52-Week Range	3.32 - 25.00
Beta	n/a
RSI	55.75
Earnings Date	Mar 13, 2026

About UroGen Pharma

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 287
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UR8

Financial Performance

In 2024, UroGen Pharma's revenue was $90.40 million, an increase of 9.29% compared to the previous year's $82.71 million. Losses were -$126.87 million, 24.1% more than in 2023.

Financial numbers in USD